Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2012

View Archived Issues

Oxygen Biotherapeutics provides update on preclinical Oxycyte studies

Solute carrier family 12 member 2 expression linked to presbycusis

Amarantus' MANF demonstrates superiority over GDNF in vivo

Theraclone Sciences begins phase II viral challenge study for TCN-032

Results of alisertib phase I/II cancer trial presented

Dosing commences in phase Ib/IIa study of KD-020

Chugai enters Japanese license agreement for CSG-452

Hokusai-VTE phase III trial reaches full enrollment

Novartis presents results of phase Ib trial of PI3K pathway inhibitors in advanced solid tumors

New GPR119 receptor agonists disclosed by Arena Pharmaceuticals

Boehringer Ingelheim patents novel DP2 receptor antagonists

Universitat Stuttgart presents new fusion proteins

Novel bispecific antibodies patented by Boehringer Ingelheim

Prostetta Antiviral discloses novel agents for viral infections

GlaxoSmithKline synthesizes new LSD1 inhibitors

Gilead provides results for third quarter of 2012

Results of phase II COPD trials presented for GSK-573719

AstraZeneca reports third quarter 2012 results

bluebird bio receives CIRM grant for lentivirus-mediated gene therapy trial

FDA approves Synribo for chronic myelogenous leukemia

FDA turns down request for appeal on NDA for vaginal gel in preterm birth

Bristol-Myers Squibb reviews highlights of third quarter 2012

Vaccinex presents in vivo data for its novel anti-CXCL13 antibody

Sandoz commences trial of biosimilar epoetin alfa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...